Major health authorities around the world are implementing or preparing to implement the next major version of eCTD for regulatory submissions. As the most consequential update to eCTD in the last two decades, it is essential for pharmaceutical and biotech companies to stay well-informed and poised to make this transition.
In this webinar, we provided a comprehensive overview of when and how each region is adopting eCTD 4.0, including the latest updates from major regulatory bodies such as US FDA, EMA, Health Canada, and Japan’s PMDA. Additionally, we shared tips and strategies for making the shift to eCTD 4.0 seamless.
Fill in our form to watch this webinar where we explored the global rollout of eCTD 4.0 and how to successfully navigate the transition.
Key Learning Objectives:
- Understand the timing for eCTD 4.0 rollout globally
- How to plan for the transition to eCTD 4.0 submissions
- Implementation differences of major health authorities
